We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Omicron BA.1, BA.2 and COVID-19 Booster Vaccination.
- Authors
Assawakosri, Suvichada; Kanokudom, Sitthichai; Suntronwong, Nungruthai; Puenpa, Jiratchaya; Duangchinda, Thaneeya; Chantima, Warangkana; Pakchotanon, Pattarakul; Mongkolsapaya, Juthathip; Wanlapakorn, Nasamon; Honsawek, Sittisak; Poovorawan, Yong
- Abstract
Graph: Figure 1. class="chapter-para">Neutralizing antibody titers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against BA.1 and BA.2 omicron variants at prebooster and 28 days postbooster. These preliminary results indicate that the heterologous booster with mRNA vaccine in AZD1222-primed individuals could induce a robust antibody response that can cross-neutralize both BA.1 and BA.2 omicron variants. To the Editor - In reply to the correspondence from Tjan et al [[1]] regarding the heterologous booster in healthy adults previously immunized with 2 doses of CoronaVac [[2]], the additional knowledge on immunogenicity of the booster (third dose) with BNT162b2 in BNT162b2-primed individuals against the BA.2 omicron variant will help promote the vaccine uptake and coverage in the midst of a surge in BA.2 omicron worldwide.
- Publication
Journal of Infectious Diseases, 2022, Vol 226, Issue 8, p1480
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiac158